HK1160110A1 - Compounds useful for inhibiting chk1 - Google Patents
Compounds useful for inhibiting chk1Info
- Publication number
- HK1160110A1 HK1160110A1 HK12100301.0A HK12100301A HK1160110A1 HK 1160110 A1 HK1160110 A1 HK 1160110A1 HK 12100301 A HK12100301 A HK 12100301A HK 1160110 A1 HK1160110 A1 HK 1160110A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds useful
- inhibiting chk1
- chk1
- inhibiting
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13817608P | 2008-12-17 | 2008-12-17 | |
| PCT/US2009/067437 WO2010077758A1 (en) | 2008-12-17 | 2009-12-10 | Compounds useful for inhibiting chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1160110A1 true HK1160110A1 (en) | 2012-08-10 |
Family
ID=42079067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12100301.0A HK1160110A1 (en) | 2008-12-17 | 2012-01-11 | Compounds useful for inhibiting chk1 |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP2379532B1 (sr) |
| JP (1) | JP5705743B2 (sr) |
| KR (1) | KR101301777B1 (sr) |
| CN (1) | CN102245597B (sr) |
| AR (1) | AR074471A1 (sr) |
| AU (1) | AU2009333433B2 (sr) |
| BR (1) | BRPI0922468A2 (sr) |
| CA (1) | CA2746423C (sr) |
| CL (1) | CL2011001463A1 (sr) |
| CO (1) | CO6382122A2 (sr) |
| CR (1) | CR20110339A (sr) |
| CY (1) | CY1113930T1 (sr) |
| DK (1) | DK2379532T3 (sr) |
| DO (1) | DOP2011000185A (sr) |
| EA (1) | EA018118B1 (sr) |
| EC (1) | ECSP11011136A (sr) |
| ES (1) | ES2401558T3 (sr) |
| HK (1) | HK1160110A1 (sr) |
| HN (1) | HN2011001446A (sr) |
| HR (1) | HRP20130167T1 (sr) |
| IL (1) | IL213160A (sr) |
| JO (1) | JO2886B1 (sr) |
| MA (1) | MA32901B1 (sr) |
| MX (1) | MX2011006603A (sr) |
| MY (1) | MY156998A (sr) |
| NZ (1) | NZ593440A (sr) |
| PA (1) | PA8850801A1 (sr) |
| PE (1) | PE20120077A1 (sr) |
| PL (1) | PL2379532T3 (sr) |
| PT (1) | PT2379532E (sr) |
| RS (1) | RS52739B (sr) |
| SG (1) | SG172222A1 (sr) |
| SI (1) | SI2379532T1 (sr) |
| TN (1) | TN2011000298A1 (sr) |
| TW (1) | TWI436996B (sr) |
| UA (1) | UA101998C2 (sr) |
| WO (1) | WO2010077758A1 (sr) |
| ZA (1) | ZA201103946B (sr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314108B2 (en) * | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
| JO3145B1 (ar) * | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| TWI725041B (zh) * | 2015-07-23 | 2021-04-21 | 美商美國禮來大藥廠 | 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 |
| TWI627168B (zh) * | 2015-12-07 | 2018-06-21 | 美國禮來大藥廠 | (s)-乳酸鹽 |
| EA201891005A1 (ru) | 2015-12-15 | 2018-12-28 | Эли Лилли Энд Компани | Комбинированная терапия рака |
| ES2906785T3 (es) | 2016-02-04 | 2022-04-20 | Pharmaengine Inc | Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones |
| US20200108074A1 (en) | 2017-03-31 | 2020-04-09 | Seattle Genetics, Inc. | Combinations of chk1- and wee1- inhibitors |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| JP7260718B2 (ja) * | 2019-11-29 | 2023-04-18 | メッドシャイン ディスカバリー インコーポレイテッド | ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用 |
| WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
| MX2023006364A (es) | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| CN117715905A (zh) | 2021-05-27 | 2024-03-15 | 无界生物公司 | 检查点激酶1（chk1）抑制剂及其用途 |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
| WO2023120696A1 (ja) * | 2021-12-24 | 2023-06-29 | 住友ファーマ株式会社 | 二環性骨格を有する１ｈ－ピラゾール－３－アミン誘導体 |
| WO2023229032A1 (ja) * | 2022-05-27 | 2023-11-30 | 住友ファーマ株式会社 | 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 |
| GB202213792D0 (en) | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| GB202403910D0 (en) | 2024-03-19 | 2024-05-01 | Benovental Cambridge Ltd | New processes and intermediates for pharmaceutical products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| MXPA06000933A (es) | 2003-07-25 | 2006-03-30 | Pfizer | Compuestos de aminopirazol y uso como inhibidores de chk1. |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| US20090270418A1 (en) * | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
-
2009
- 2009-11-26 PA PA20098850801A patent/PA8850801A1/es unknown
- 2009-12-01 JO JO2009456A patent/JO2886B1/en active
- 2009-12-03 TW TW098141394A patent/TWI436996B/zh active
- 2009-12-03 AR ARP090104673A patent/AR074471A1/es not_active Application Discontinuation
- 2009-12-10 EP EP09768586A patent/EP2379532B1/en active Active
- 2009-12-10 EA EA201170834A patent/EA018118B1/ru not_active IP Right Cessation
- 2009-12-10 UA UAA201107564A patent/UA101998C2/ru unknown
- 2009-12-10 PT PT97685861T patent/PT2379532E/pt unknown
- 2009-12-10 PL PL09768586T patent/PL2379532T3/pl unknown
- 2009-12-10 ES ES09768586T patent/ES2401558T3/es active Active
- 2009-12-10 PE PE2011001140A patent/PE20120077A1/es active IP Right Grant
- 2009-12-10 NZ NZ593440A patent/NZ593440A/xx not_active IP Right Cessation
- 2009-12-10 SI SI200930559T patent/SI2379532T1/sl unknown
- 2009-12-10 MY MYPI2011002767A patent/MY156998A/en unknown
- 2009-12-10 CN CN200980150018.7A patent/CN102245597B/zh active Active
- 2009-12-10 AU AU2009333433A patent/AU2009333433B2/en not_active Ceased
- 2009-12-10 DK DK09768586.1T patent/DK2379532T3/da active
- 2009-12-10 BR BRPI0922468-8A patent/BRPI0922468A2/pt active Search and Examination
- 2009-12-10 WO PCT/US2009/067437 patent/WO2010077758A1/en active Application Filing
- 2009-12-10 CA CA2746423A patent/CA2746423C/en not_active Expired - Fee Related
- 2009-12-10 RS RS20130153A patent/RS52739B/sr unknown
- 2009-12-10 JP JP2011542264A patent/JP5705743B2/ja active Active
- 2009-12-10 KR KR1020117013801A patent/KR101301777B1/ko active IP Right Grant
- 2009-12-10 SG SG2011044401A patent/SG172222A1/en unknown
- 2009-12-10 MX MX2011006603A patent/MX2011006603A/es active IP Right Grant
-
2011
- 2011-05-26 IL IL213160A patent/IL213160A/en not_active IP Right Cessation
- 2011-05-27 ZA ZA2011/03946A patent/ZA201103946B/en unknown
- 2011-06-01 HN HN2011001446A patent/HN2011001446A/es unknown
- 2011-06-10 TN TN2011000298A patent/TN2011000298A1/fr unknown
- 2011-06-13 DO DO2011000185A patent/DOP2011000185A/es unknown
- 2011-06-14 MA MA33944A patent/MA32901B1/fr unknown
- 2011-06-15 CO CO11074829A patent/CO6382122A2/es active IP Right Grant
- 2011-06-16 EC EC2011011136A patent/ECSP11011136A/es unknown
- 2011-06-16 CL CL2011001463A patent/CL2011001463A1/es unknown
- 2011-06-17 CR CR20110339A patent/CR20110339A/es unknown
-
2012
- 2012-01-11 HK HK12100301.0A patent/HK1160110A1/xx unknown
-
2013
- 2013-02-27 HR HRP20130167AT patent/HRP20130167T1/hr unknown
- 2013-04-11 CY CY20131100305T patent/CY1113930T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1160110A1 (en) | Compounds useful for inhibiting chk1 | |
| GB0807862D0 (en) | Compounds | |
| GB0800035D0 (en) | Compounds | |
| IL231955A0 (en) | Tetracycline compounds are substituted at the 7c position with fluorine | |
| GB0804702D0 (en) | Compounds | |
| PT2638033E (pt) | Compostos úteis para inibir chk1 | |
| GB0807103D0 (en) | Compounds | |
| GB0800367D0 (en) | Compounds | |
| EP2192904A4 (en) | METHODS OF INHIBITING TGF- | |
| GB0801220D0 (en) | Compounds | |
| GB0801265D0 (en) | Compounds | |
| IL210015A0 (en) | Substituted cyclohexylidene-ethylidene-octahydro-indene compounds | |
| EP2299809A4 (en) | SUBSTITUTED CYCLOHEXYLIDES-ETHYLIDES-OCTAHYDROINDENE COMPOUNDS | |
| GB0804064D0 (en) | Compounds | |
| GB0801596D0 (en) | Compounds | |
| GB0805048D0 (en) | Niovel compounds | |
| GB0805311D0 (en) | Compounds | |
| GB0802192D0 (en) | Compounds | |
| GB0802231D0 (en) | Compounds | |
| GB0802586D0 (en) | Compounds | |
| GB0802587D0 (en) | Compounds | |
| GB0803493D0 (en) | Compounds | |
| GB0803495D0 (en) | Compounds | |
| GB0803496D0 (en) | Compounds | |
| GB0801219D0 (en) | Compounds |